Intermediate-Size Expanded Access Protocol (EAP) for LP352
NCT ID: NCT06149663
Last Updated: 2025-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
AVAILABLE
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
NCT05364021
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
NCT05626634
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LP352
LP352 will be administered as a liquid either orally or through a G-tube or Percutaneous Endoscopic Gastrotomy (PEG) tube.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Participant with DEE who has successfully completed an LP352 Clinical Trial.
3. Participant currently has clinical benefit from LP352 treatment, as assessed by their Treating Physician.
4. Participant currently tolerates LP352 treatment and has no safety issue which would prevent continued treatment.
Exclusion Criteria
2. Any serious and/or unstable new medical condition, psychiatric disorder, or other conditions at the time of transition to this EAP that could interfere with patient's safety, obtaining informed consent, assent, or compliance to this EAP protocol, in the opinion of the Treating Physician.
2 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Longboard Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rancho Research Institute
Downey, California, United States
University of California Los Angeles (UCLA)
Los Angeles, California, United States
University of California Benioff Childrens Hospital
San Francisco, California, United States
Colorados Childrens Hospital
Aurora, Colorado, United States
Northwest Florida Clinical Research Group
Gulf Breeze, Florida, United States
Research Institute of Orlando
Orlando, Florida, United States
University of Southern Florida
Tampa, Florida, United States
Hawaii Pacific Neuroscience
Honolulu, Hawaii, United States
Northwestern Medicine Feinberg School of Medicine
Chicago, Illinois, United States
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland, United States
Corewell Health
Grand Rapids, Michigan, United States
Washington University School of Medicine
St Louis, Missouri, United States
New York University (NYU)
New York, New York, United States
Lenox Hill Hospital
New York, New York, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Providence Brain & Spine
Portland, Oregon, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Children's Neuro Consultants of Austin
Austin, Texas, United States
University of Utah
Salt Lake City, Utah, United States
Austin Hospital, Heidelberg
Heidelberg, Melbourne, Australia
Alfred Hospital
Melbourne, Melbourne, Australia
Children's Health Queensland Hospital and Health Service,
South Brisbane, Queensland, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LP352-EAP-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.